The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

An analyst's downbeat new take on Summit Therapeutics ( SMMT -11.32%) pushed its stock downward on Hump Day. At the end of ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The stock's fall snapped a three-day winning streak.

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

The world-travelling Curiosity Cube is now in Soweto until the end of June where learners can access fun STEM experiments and ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...